Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, Competitive Landscape and Market Forecast - 2029

Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market is segmented By Product (Calcium Channel Á2-delta Ligands, Antidepressants, Opioids, Others), By Application (Platinum Agents, Taxanes, Vinca Alkaloids, Others), By End-Users (Hospitals & Clinics, Cancer Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Market Overview

The Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market is expected to grow at a CAGR of 5% during the forecasting period (2022-2029).

Chemotherapy-induced peripheral neuropathy is a serious clinical problem induced by the number of chemotherapeutics drugs or cytotoxic drugs such as platinum, taxanes, and vinca alkaloids eribulin, epothilones, and bortezomib. These drugs cause different pathological problems to the neurons. The pathological problems lead to the degeneration of peripheral sensory and motor nerves and cause patients to present with sensory disturbances, balance problems, or weakness.

 

Market Dynamics

The technological advancement in the treatment and diagnosis of cancer and the rising incidence of chemotherapy-induced peripheral neuropathy is expected to propel the market growth. Moreover, the increasing demand for cost-efficient therapeutics in emerging regions acts as an opportunity for market growth. However, the adverse effect associated with the treatment may hamper the global chemotherapy-induced peripheral neuropathy treatment market.

Continuous rise in R&D will continue supporting the growth of the market during the forecast period.

The companies operating in the chemotherapy-induced peripheral neuropathy market are making constant efforts to develop efficient drugs and medications to manage chemotherapy. The presence of cancerous cells in the body makes it critical to administer minor doses of drugs for administering peripheral neuropathy. Henceforth, the key market players in the global chemotherapy-induced peripheral neuropathy market are ramping up their oncological research investments.

Collaboration with research institutes is driving the growth of the global market.

Harvard Health Reviews have been offering relevant signals for the management and treatment of neuropathy. Numerous companies in the chemotherapy-induced peripheral neuropathy market are expected to collaborate with Harvard’s research fraternity to reap the benefits of collaborative research. The Harvard Medical School insights have already helped numerous companies and research units and chemotherapy-induced peripheral neuropathy'stand nature and uropathy.

COVID-19 Impact Analysis

The outbreak of COVID-19 has certainly impacted the global chemotherapy-induced peripheral neuropathy treatment market, as the lockdown has compelled the diagnosis of new cancer cases, which in turn has derailed the adoption rate of chemotherapy-induced peripheral neuropathy treatment amidst the COVID-19 pandemic. Therefore, the chemotherapy-induced peripheral neuropathy treatment market is expected to foresee a considerable decline in 2020.

Segment Analysis

Based on the product, the chemotherapy-induced peripheral neuropathy treatment market has been classified into calcium channel Á2-delta ligands, antidepressants, opioids, and others.

The antidepressants segment accounted for the highest market share in the global market.

Antidepressant contributes the major share in the chemotherapy-induced peripheral neuropathy treatment market. It has a 'clinically meaningful effect on chemotherapy-induced peripheral neuropathy. Adjunct treatment options for chemotherapy-induced peripheral neuropathy include a topical analgesic, a tricyclic antidepressant, an anticonvulsant, or an SNRI. Therefore, realizing the potential benefits of chemotherapy-induced peripheral neuropathy as an antidepressant will drive the market growth during the forecast period.

The chemotherapy-induced peripheral neuropathy treatment market has been classified into platinum agents, taxanes, vinca alkaloids, and others based on the application.

Platinum Agents segment dominated the global chemotherapy-induced peripheral neuropathy treatment market in 2019

In the chemotherapy-induced peripheral neuropathy treatment market, the major application is platinum agents. Platinum agents (carboplatin, cisplatin, and oxaliplatin) are a class of chemotherapy agents with a wide range of activity against several solid tumors. Toxicity to the peripheral nervous system is the key dose-reducing toxicity of a few of the platinum drugs of clinical interest. Among the platinum compounds, cisplatin is considered the most neurotoxic, inducing mainly sensory neuropathy of the upper and lower extremities.

 

Geographical Analysis

Based on geography, the study analyzes the chemotherapy-induced peripheral neuropathy treatment market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America leads the global market throughout the forecast period.

North America dominated the global chemotherapy-induced peripheral neuropathy treatment market and is expected to retain its position during the forecast period. The U.S. contributed over 86.0% to the North American chemotherapy-induced peripheral neuropathy treatment market in 2019. The increase in the incidence and prevalence rate of different cancer has led to a rise in demand for cancer drugs. This growth is due to chemotherapy in earlier cancer treatment stages compared to other therapy options such as immunological therapy drugs and targeted therapy drugs used in the late stage.

The Asia Pacific is estimated to grow at a considerable growth rate in the chemotherapy-induced peripheral neuropathy treatment market during the forecast period. This growth can be accredited to the rapidly developing healthcare infrastructure and rising awareness programs in this region. Further, growing medical tourism in developing countries such as India, China, Singapore, and Malaysia is also estimated to positively youth the global chemotherapy-induced peripheral neuropathy treatment market.

Competitive Landscape

The chemotherapy-induced peripheral neuropathy treatment market is highly competitive. The key chemotherapy-induced peripheral neuropathy treatment players contributing to the global market's growth market include Regency Pharmaceuticals, Nemus Bioscience Inc, PledPharma, Immune PharmaceIncnc., and DermaXon LLC. The major players are adopting new product launch and expansion strategies for global growth in the chemotherapy-induced peripheral neuropathy treatment market.   

PledPharma

Overview: 

PledPharma develops various pharmaceutical products to treat various life-threatening diseases. It primarily develops PledOx in Phase IIb clinical trials to reduce severe side therapy in patients dealing with colorectal cancer. The company’s project pipeline comprises Aladote (PP-100), which is in Phase II clinical trials for treating acute liver failure in conjunction with acetaminophen poisoning, and PP-099 has completed Phase IIa clinical trials for the treatment of acute myocardial infarction.

Product Portfolio: The company manufactures numerous products, including PledOx.

Trending Topics

Peripheral Neuropathy Market

U.S. Peripheral CTO Device Market